Beyond binding – iPSC-based functional safety screening for oncology modalities

Thursday, January 22 at 15:00 GMT | 16:00 CET | 10:00 EST | 07:00 PST

Biologics and cell-based therapeutics are expanding rapidly across oncology, yet early detection of safety liabilities remains a critical challenge. Off-target interactions and low-level antigen expression in healthy tissues can lead to severe clinical setbacks.

Recent FDA guidance emphasizes the need for human-relevant in vitro systems to assess functional toxicities before entering clinical trials. Induced pluripotent stem cell (iPSC)-derived models provide a reproducible, scalable solution for multi-tissue safety evaluation, including cardiac risk assessment.

In this webinar, industry experts will explore current challenges in oncology safety testing and the evolving regulatory landscape. They will introduce a novel iPSC-derived multi-tissue functional safety screening platform and demonstrate how comprehensive kinetic cardiac profiling can mitigate risk prior to clinical development, supported by case studies on antibody-drug conjugates (ADCs) and kinase inhibitors.

Key learning objectives

• Understand the current challenges and regulatory expectations for in vitro safety testing in oncology drug development.
• Learn how iPSC-derived multi-tissue models overcome limitations of traditional systems and improve translational relevance.
• Gain insights into integrating multi-tissue safety screening into drug development workflows and support regulatory alignment.
• Discover how early cardiac safety profiling can guide program decision and inform risk mitigation.

Who should attend?

• Big pharma: in vitro translational, pharmacology, toxicology and safety teams
• Biotechnology companies: in vitro translational, pharmacology, toxicology and safety teams
• Regulatory agencies employees: EMA and FDA
• Non-profit research organizations/foundations in oncology
• Oncology advocatory groups
  

Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.